modelIrinotecan
Extends from Pharmacolibrary.Drugs.ATC.L.L01CE02.
Information
| name: | Irinotecan | |
| ATC code: | L01CE02 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 350 | mg |
| volume of distribution: | 107 | L |
| clearance: | 13.2 | L/h |
| other parameters in model implementation | ||
Irinotecan is a semisynthetic derivative of camptothecin and acts as a topoisomerase I inhibitor. It is primarily used as a chemotherapeutic agent for the treatment of colorectal cancer, among other solid tumors. Irinotecan is approved for use in multiple countries for metastatic colorectal cancer, often in combination with other agents (e.g., 5-fluorouracil and leucovorin).
Pharmacokinetics
Population pharmacokinetic parameters for total irinotecan in adult patients with solid tumors, following intravenous infusion.
References
Sathe, AG, et al., & Othman, AA (2024). Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors. Clinical pharmacokinetics 63(5) 669–681. DOI:10.1007/s40262-024-01366-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38578394
Karas, S, et al., & Innocenti, F (2022). Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients. British journal of cancer 126(4) 640–651. DOI:10.1038/s41416-021-01589-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34703007
Xie, R, et al., & Karlsson, MO (2002). Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20(15) 3293–3301. DOI:10.1200/JCO.2002.11.073 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12149304
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)